載入...
Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
Objective: Despite the promise of PARP inhibitors (PARPi) for treating BRCA1/2 mutated ovarian cancer (OC), drug resistance invariably develops. We hypothesized rationale drug combinations, targeting key molecules in DNA repair pathways and the cell cycle may be synergistic and overcome acquired PAR...
Na minha lista:
| 發表在: | Diagnostics (Basel) |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7168282/ https://ncbi.nlm.nih.gov/pubmed/32098452 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/diagnostics10020121 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|